2022 World Conference on Lung Cancer (ePosters)-EP08.02-008. Tumor Invasiveness and Clinical Outcomes between Metastatic ROS-1 and ALK Positive NSCLC

Pdf Summary

This study aimed to compare the tumor invasiveness and clinical outcomes between metastatic ROS-1 positive non-small cell lung cancer (NSCLC) and ALK positive NSCLC. The study collected data from 40 patients with ROS-1 positive NSCLC and 45 patients with ALK positive NSCLC, all of whom had distant metastases.<br /><br />The results showed that there was no significant difference in baseline disease burden between the two groups. However, patients with ALK positive NSCLC had a more unfavorable prognosis and were more likely to develop central nervous system (CNS) progression compared to those with ROS-1 positive NSCLC following treatment with crizotinib, a tyrosine kinase inhibitor.<br /><br />In terms of tumor invasiveness, there were no significant differences in the percentage of extrathoracic metastases, CNS metastases, multiple CNS metastases, measurable CNS lesions, liver metastases, bone metastases, or three distant organs involved between the two groups.<br /><br />The progression-free survival of crizotinib as an initial tyrosine kinase inhibitor was shown to be longer in patients with ROS-1 positive NSCLC compared to those with ALK positive NSCLC. Additionally, the CNS time to progression on crizotinib was longer in patients with ROS-1 positive NSCLC compared to those with ALK positive NSCLC, both with and without baseline CNS metastases.<br /><br />The incidence of secondary mutations in the kinase domain or solvent front mutation was similar between the two groups.<br /><br />In conclusion, patients with ALK positive NSCLC had a worse prognosis and were more prone to develop CNS progression compared to those with ROS-1 positive NSCLC following treatment with crizotinib. These findings provide important insights into the differences in tumor invasiveness and clinical outcomes between metastatic ROS-1 and ALK positive NSCLC.

Asset Subtitle

Zihua Zou

Meta Tag

Speaker Zihua Zou

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

metastatic ROS-1 positive non-small cell lung cancer

ALK positive NSCLC

tumor invasiveness

clinical outcomes

distant metastases

baseline disease burden

prognosis

central nervous system progression

crizotinib

tyrosine kinase inhibitor